The Critical Role of Androgens in Prostate Development

Endocrinology and Metabolism Clinics of North America

Volumn 40, Issue 3, 2011, Pages 577-590

  Wilson, Jean D ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Androgen; Androgen receptor; Dihydrotestosterone; Leydig cell; Testosterone; Urogenital sinus

Indexed keywords

ACTIVIN; ANDROGEN; ANDROSTANOLONE; ESTRADIOL; FIBROBLAST GROWTH FACTOR 10; HEPATOCYTE NUCLEAR FACTOR 3BETA; JAGGED1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SONIC HEDGEHOG PROTEIN; STEROID 5ALPHA REDUCTASE; TESTOSTERONE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR HOXA13; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; WNT PROTEIN;

ANDROGEN METABOLISM; BULBOURETHRAL GLAND; EMBRYO DEVELOPMENT; HISTOPATHOLOGY; HUMAN; LEYDIG CELL; MESENCHYME; MUELLERIAN DUCT; NONHUMAN; ORGAN WEIGHT; ORGANOGENESIS; PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY; PROSTATE VENTRAL LOBE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; SEMINAL VESICLE; SEX DIFFERENTIATION; SEXUAL MATURATION; SIGNAL TRANSDUCTION; VAS DEFERENS;

AGING; ANDROGENS; ANIMALS; DIHYDROTESTOSTERONE; DOGS; HUMANS; MALE; MODELS, BIOLOGICAL; PROSTATE; RECEPTORS, ANDROGEN;

CANIS FAMILIARIS;

EID: 80052229450     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2011.05.003     Document Type: Review

References (72)

1. Lowsley O.S. The development of the human prostate gland with reference to the development of other structures at the neck of the urinary bladder. Am J Anat 1912, 8:526-541.
2. Johnson F.P. The later development of the urethra in the male. J Urol 1920, 4:447-501.
3. Coffey D.S. The molecular biology, endocrinology, and physiology of the prostate and seminal vesicles. Campbell's urology 1991, 221-266. WB Saunders, Philadelphia. 6th edition. P.C. Walsh, A.B. Retik, T.A. Stamey (Eds.).
4. Cai Y. Participation of caudal mullerian mesenchyma in prostate development. J Urol 2008, 180:1898-1903.
5. Levine A., Wang J.P., Ren M., et al. Immunohistochemical localization of steroid 5α-reductase 2 in the human male fetal reproductive tract and adult prostate. J Clin Endocrinol Metab 1996, 81:384-389.
6. Tyndale-Biscoe H., Renfree M.B. Reproductive physiology of marsupials 1987, Cambridge University Press, London, p. 147-9.
7. Leydig F. Zur anatomie der Mannlichen geschlechtorgane und analdrusen der saugetiere. Z Wiss Zool 1850, 2:1-57. [in German].
8. Setchell B.P. Male reproduction 1984, Van Nostrand Reinhold Inc, New York, p. 219-20.
9. Bouin P., Ancel P. Rescherches sur les cellules interstititielles du testicule des mammiferes. Arch Zool Exp Gen Ser A 1903, 1:437-523. [in French].
10. Bouin P., Ancel P. C R Seances Soc Biol Fil 1903, 55:1682-1684. [in French].
11. Jost A. Problems of fetal endocrinology: the gonadal and hypophyseal hormones. Recent Prog Horm Res 1953, 8:379-413.
12. Jost A. The role of hormones in prenatal development. Harvey Lect 1961, 55:201-226.
13. Jost A. Hormonal factors in the sex differentiation of the mammalian foetus. Philos Trans R Soc Lond B Biol Sci 1970, 259:119-130.
14. Josso N., Belville C., di Clemente N., et al. AMH and AMH receptor defects in persistent Mullerian duct syndrome. Hum Reprod Update 2005, 11:351-356.
15. Josso N., Picard J.Y., Rey R., et al. Testicular anti-Mullerian hormone: history, genetics, regulation and clinical applications. Pediatr Endocrinol Rev 2006, 3:347-358.
16. Griffin J.E., McPhaul M.J., Russell D.W., et al. The androgen resistance syndromes: steroid 5α-reductase 2 deficiency, testicular feminization, and related disorders. The metabolic and molecular bases of interited disease 2001, 4117-4146. McGraw-Hill, New York. 8th edition. C.R. Scriver, A.L. Beaudet, W.S. Sly (Eds.).
17. Goldstein J.L., Wilson J.D. Studies on the pathogenesis of the pseudohermaphroditismin the mouse with testicular feminization. J Clin Invest 1972, 51:1647-1658.
18. Schultz F.M., Wilson J.D. Virilization of the wolffian duct in the rat fetus by various androgens. Endocrinology 1974, 94:979-986.
19. Leihy M.W., Shaw G., Wilson J.D., et al. Virilisation of the urogenital sinus of the tammar wallaby is not unique to 5α-androstane-3α,17β-diol. Mol Cell Endocrinol 2001, 181:111-115.
20. Nimkarn S., Lin-Su K., New M.I. Steroid 21 hydroxylase deficiency congenital adrenal hyperplasia. Endocrinol Metab Clin North Am 2009, 38:699-718.
21. Swyer G.J. Postnatal growth in the human prostate. J Anat 1944, 78:130-145.
22. Huggins C. The etiology of benign prostatic hypertrophy. Bull N Y Acad Med 1947, 23:1022-1026.
23. Cabot A.T. The question of castration for enlarged prostate. Ann Surg 1896, 24:265-309.
24. Peters C.A., Walsh P.C. The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. N Engl J Med 1987, 317:599-604.
25. Gabrilove J.L., Levine A.C., Kirchenbaum A., et al. Effect of a GnRH analogue (leuprolide) on benign prostatic hypertrophy. J Clin Endocrinol Metab 1987, 64:1331-1333.
26. Hikmet, Regnault F. Les eunuchs de constantinople. Bull Mem Soc Anthropol Paris. 5th series 1901, 12:232-240. [in French].
27. Wagenseil F. Bitrage zur Kenntnis der Kastrationsfolgen und des Eunuchoidismus beim Mann. Z Morphol Anthropol 1927, 26:264-301. [in German].
28. Wu C.P., Gu F.L. The prostate 41-65 years post castration: an analysis of 26 eunuchs. Chin Med J (Engl) 1967, 100:271-272.
29. Wu C.P., Gu F.L. The prostate in eunuchs. EORTC genitourinary group monograph 10 1991, Wiley-Liss, New York, p. 249-55.
30. Moore R.J., Wilson J.D. The effect of androgenic hormones on the reduced nicotinamide adenine dinuclotide phosphate: Δ4-3-ketosteroid 5α-oxidoreductase of rat ventral prostate. Endocrinology 1973, 93:581-592.
31. Wilson J.D., Roehrborn C. Long term consequences of castration in men: lessons from the Skoptzy and the eunuchs of the Chinese and Ottoman courts. J Clin Endocrinol Metab 1999, 84:4324-4331.
32. Wilson J.D. Metabolism of testicular androgens. Handbook of physiology, sect 7 1975, vol. 5:491-508. Ameican Physiological Society, Washington, DC. R.O. Greep, E.B. Astwood (Eds.).
33. Siiteri P.K., Wilson J.D. Testosterone formation and metabolism during male sexual differentiation in the human embryo. J Clin Endocrinol Metab 1974, 38:113-125.
34. Andersson S., Bishop K.W., Russell D.W. Expression cloning and regulation of steroid 5 alpha-reductase, an enzyme essential for male sexual differentiation. J Biol Chem 1989, 264:16249-16255.
35. Jenkins E.P., Andersson S., Imperato-McGinley J., et al. Genetic and pharmacological evidence for more than one human steroid 5α-reductase. J Clin Invest 1992, 89:293-300.
36. Andersson S., Berman D.M., Jenkins E.P., et al. Deletion of steroid 5α-reductase 2 gene in male pseudohermaphroditism. Nature 1991, 354:159-161.
37. Thigpen A.E., Silver R.I., Ruileyardo J.M., et al. Tissue distribution and ontogeny of steroid 5α-reductase isoenzyme expression. J Clin Invest 1993, 92:903-910.
38. Imperato-McGinley J., Miller M., Wilson J.D., et al. A cluster of male pseudohermahroditism with 5α-reductase deficiency in Papua New Guinea. Clin Endocrinol (Oxf) 1991, 34:293-298.
39. Thigpen A.E., Davis D.L., Milatovich A., et al. Molecular genetics of steroid 5α-reductase 2 deficiency. J Clin Invest 1992, 90:799-809.
40. Price P., Wass J.A.H., Griffin J.E., et al. High dose androgen therapy in male pseudoermaphroditism due to 5α-reductase deficiency and disorders of the androgen receptor. J Clin Invest 1984, 74:1496-1508.
41. Shaw G., Renfree M.B., Leihy M.W., et al. Prostate formation in a marsupial is mediated by the testicular androgen 5α-androstane-3α,17β-diol. Proc Natl Acad Sci U S A 2000, 97:1236-1239.
42. Bruchovsky N. Comparison of the metabolites formed in rat prostate following the in vivo administration of seven natural androgens. Endocrinology 1971, 89:1212-1222.
43. Liao S., Fang S. Receptor-proteins for androgens and the mode of action of androgens on gene transcription in ventral prostate. Vitam Horm 1969, 27:18-90.
44. Grino P.B., Griffin J.E., Wilson J.D. Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone. Endocrinology 1990, 126:1165-1172.
45. Deslypere J.-P., Young M., Wilson J.D., et al. Testosterone and 5α-dihydrotestosterone interact differently with the androgen receptor to enhance transcription of the MMTV-CAT reporter gene. Mol Cell Endocrinol 1992, 88:15-22.
46. Mahendroo M.S., Cala K.M., Hess D.L., et al. Unexpected virilization in male mice lacking steroid 5α-reductase enzymes. Endocrinology 2001, 142:4652-4662.
47. McConnell J.D., Wilson J.D., George F.W., et al. Finasteride, an inhibitor of 5α-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 1992, 74:505-508.
48. Gao T.S., McPhaul M.J. Functional activities of the A- and B-forms of the human androgen receptor in response to androgen receptor agonists and antagonists. Mol Endocrinol 1998, 12:654-663.
49. Rosner W., Hryb D.J., Kahn S.M., et al. Interaction of sex hormone-binding globulin with target cells. Mol Cell Endocrinol 2010, 316:79-85.
50. Griffin J.E. Androgen resistance-the clinical and molecular spectrum. N Engl J Med 1992, 326:611-618.
51. Michels G., Hoppe U.C. Rapid actions of androgens. Front Neuroendocrinol 2008, 29:182-198.
52. Rahman F., Christian H.C. Non-classical actions of testosterone: an update. Trends Endocrinol Metab 2007, 18:371-378.
53. Cunha G.R. Mesenchymal-epithelial interactions: past, present, and future. Differentiation 2008, 76:568-586.
54. Fleischmajer R., Billingham R.E. Epithelial-mesenchyme interactions 1968, Williams & Wilkins, Baltimore (MD).
55. Cunha G.R. Epithelio-mesenchymal interactions in developing accessory sexual gland structures which become responsive to androgenic stimulation. Anat Rec 1972, 172:179-196.
56. Cunha G.R., Battle E., Young P., et al. Role of epithelial-mesenchymal interactions in the differentiation and spatial organization of visceral smooth muscle. Epithelial Cell Biol 1992, 1:76-83.
57. Thomson A.A. Mesenchymal mechanisms in prostate organogenesis. Differentiation 2008, 76:587-598.
58. Hogan B.L. Morphogenesis. Cell 1999, 96:225-233.
59. Prins G.S., Putz O. Molecular signaling pathways that regulate prostate gland development. Differentiation 2008, 76:641-659.
60. Huang K., Pu Y., Birch L., et al. Posterior Hox gene expression and differential androgen regulation in the developing and adult rat prostate lobes. Endocrinology 2007, 148:1235-1245.
61. Pu Y., Huang L., Prins G.S. Androgen regulation of prostate morphoregulatory gene expression: Fgf10-dependent and -independent pathways. Endocrinology 2007, 148:1697-1706.
62. Gao N., Ishii K., Mirosevich J., et al. Forkhead box A1 regulates prostate ductal morphogenesis and promotes epithelial cell maturation. Development 2005, 132:4331-4343.
63. Wang X.D., Leow C.C., Zha J., et al. Notch signaling is required for normal prostatic epithelial cell proliferation and differentiation. Dev Biol 2006, 290:66-80.
64. Gloyna R.E., Wilson J.D. A comparative study of the conversion of testosterone to 17β-hydroxy-5α-androstane-3-one (dihydrotestosterone) by prostate and epididymis. J Clin Endocrinol Metab 1969, 29:970-977.
65. Wilson J.D., Gloyna R.E. The intranuclear metabolism of testosterone in the accessory organs of reproduction. Recent Prog Horm Res 1970, 26:309-336.
66. Wilson J.D. The pathogenesis of prostatic hyperplasia. Am J Med 1980, 68:745-756.
67. Wenderoth U.K., George F.W., Wilson J.D. The effect of a 5α-reductase inhibitor on androgen-mediated growth of the dog prostate. Endocrinology 1983, 113:569-573.
68. Gonzalez G., Guendulain C., Maffrand C., et al. Comparison of the effect of the aromatase inhibitor, anastrazole, to the antiestrogen, tamoxifen citrate, on canine prostate and semen. Reprod Domest Anim 2009, 44(Suppl 2):316-319.
69. McConnell J.D., Brushewitz R., Walsh P., et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998, 338:557-563. for the Finasteride Long-Term Efficacy and Safety Study Group.
70. El Etreby M.F., Nishing Y., Habenicht U., et al. Atamestane, a new aromatase inhibitor for the management of benign prostatic hyperplasia. J Androl 1991, 12:403-414.
71. Gingell J.C., Knonagel H., Kurth K.H., et al. Placebo controlled double-blind study to test the efficacy of the aromatase inhibitor atamestane in patients with benign prostatic hyperplasia not requiring operation. J Urol 1995, 154:399-401.
72. Radlmaier A., Eickenberg H.U., Fletcher M.S., et al. Estrogen reduction by aromatase inhibition for benign prostatic hyperplasia: results of a double-blind, placebo-controlled, randomized clinical trial using two doses of the aromatase-inhibitor atamestane. Prostate 1996, 29:199-208. for the atamestane study group.